Clinical Trial

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-08-28; most recent amendment 2024-05-14.
Trial Details
NCT Number NCT05520892
Lead Sponsor Fujian Medical University Union Hospital
Collaborators: The First Affiliated Hospital of Xiamen University, Zhangzhou Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital, Nanping First Hospital Affiliated to Fujian Medical University, The Second Hospital of Anhui Medical University, The Affiliated Hospital Of Guizhou Medical University, Longyan City First Hospital, The Affiliated Hospital of Putian University
Conditions Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment
Enrollment 580 participants
Start Date 2022-10-06
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-16